Validation of a method evaluating T cell metabolic potential in compliance with ICH Q2 (R1).
Fiche publication
Date publication
janvier 2021
Journal
Journal of translational medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GODET Yann, Dr GALAINE Jeanne
Tous les auteurs :
Mercier-Letondal P, Marton C, Godet Y, Galaine J
Lien Pubmed
Résumé
Metabolic cell features are able to give reliable information on cell functional state. Thus, metabolic potential assessment of T cells in malignancy setting represents a promising area, especially in adoptive cell therapy procedures. Easy to set up and convenient Seahorse technology have recently been proposed by Agilent Technologies and it could be used to monitor T cells metabolic potential. However, this method demonstrates an inter-assay variability and lacks practices standardization.
Mots clés
Control material, T cell based immunotherapies, T cell metabolic potential
Référence
J Transl Med. 2021 Jan 6;19(1):21